🎉 M&A multiples are live!
Check it out!

ADC Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for ADC Therapeutics and similar public comparables like Julphar, Benevolent AI, and Galapagos.

ADC Therapeutics Overview

About ADC Therapeutics

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.


Founded

2011

HQ

United States of America
Employees

265

Financials

LTM Revenue $71.6M

LTM EBITDA n/a

EV

-$8.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ADC Therapeutics Financials

ADC Therapeutics has a last 12-month revenue of $71.6M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, ADC Therapeutics achieved revenue of $70.8M and an EBITDA of -$103M.

ADC Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ADC Therapeutics valuation multiples based on analyst estimates

ADC Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $69.6M $70.8M XXX XXX XXX
Gross Profit $205M $67.0M XXX XXX XXX
Gross Margin 295% 95% XXX XXX XXX
EBITDA -$146M -$103M XXX XXX XXX
EBITDA Margin -210% -145% XXX XXX XXX
Net Profit -$156M -$240M XXX XXX XXX
Net Margin -224% -339% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ADC Therapeutics Stock Performance

As of April 15, 2025, ADC Therapeutics's stock price is $1.

ADC Therapeutics has current market cap of $120M, and EV of -$8.0M.

See ADC Therapeutics trading valuation data

ADC Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$8.0M $120M XXX XXX XXX XXX $-1.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ADC Therapeutics Valuation Multiples

As of April 15, 2025, ADC Therapeutics has market cap of $120M and EV of -$8.0M.

ADC Therapeutics's trades at -0.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate ADC Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ADC Therapeutics and 10K+ public comps

ADC Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$8.0M XXX XXX XXX
EV/Revenue -0.1x XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ADC Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ADC Therapeutics Valuation Multiples

ADC Therapeutics's NTM/LTM revenue growth is 8%

ADC Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, ADC Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ADC Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ADC Therapeutics and other 10K+ public comps

ADC Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2% XXX XXX XXX XXX
EBITDA Margin -145% XXX XXX XXX XXX
EBITDA Growth -30% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -136% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue 30% XXX XXX XXX XXX
G&A Expenses to Revenue 91% XXX XXX XXX XXX
R&D Expenses to Revenue 155% XXX XXX XXX XXX
Opex to Revenue 275% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ADC Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ADC Therapeutics M&A and Investment Activity

ADC Therapeutics acquired  XXX companies to date.

Last acquisition by ADC Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . ADC Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ADC Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ADC Therapeutics

When was ADC Therapeutics founded? ADC Therapeutics was founded in 2011.
Where is ADC Therapeutics headquartered? ADC Therapeutics is headquartered in United States of America.
How many employees does ADC Therapeutics have? As of today, ADC Therapeutics has 265 employees.
Who is the CEO of ADC Therapeutics? ADC Therapeutics's CEO is Mr. Ameet Mallik.
Is ADC Therapeutics publicy listed? Yes, ADC Therapeutics is a public company listed on NYS.
What is the stock symbol of ADC Therapeutics? ADC Therapeutics trades under ADCT ticker.
When did ADC Therapeutics go public? ADC Therapeutics went public in 2020.
Who are competitors of ADC Therapeutics? Similar companies to ADC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ADC Therapeutics? ADC Therapeutics's current market cap is $120M
What is the current revenue of ADC Therapeutics? ADC Therapeutics's last 12-month revenue is $71.6M.
What is the current EV/Revenue multiple of ADC Therapeutics? Current revenue multiple of ADC Therapeutics is -0.1x.
What is the current revenue growth of ADC Therapeutics? ADC Therapeutics revenue growth between 2023 and 2024 was 2%.
Is ADC Therapeutics profitable? Yes, ADC Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.